BDNF exon IV promoter methylation and antidepressant action: a complex interplay

BACKGROUND: BDNF exon IV promoter methylation is a potential biomarker for treatment response to antidepressants in MDD. We have previously shown CpG-87 methylation as a successful biomarker for the prediction of non-response to monoaminergic antidepressants like the SSRI Fluoxetine or the SNRI Venl...

Descripción completa

Detalles Bibliográficos
Autores principales: Pathak, Hansi, Borchert, Anton, Garaali, Sara, Burkert, Alexandra, Frieling, Helge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793565/
https://www.ncbi.nlm.nih.gov/pubmed/36572893
http://dx.doi.org/10.1186/s13148-022-01415-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793565/
https://www.ncbi.nlm.nih.gov/pubmed/36572893
http://dx.doi.org/10.1186/s13148-022-01415-3

Ejemplares similares